miR-155 as a Biomarker in B-Cell Malignancies

Table 2

miR-155 as diagnostic biomarker in B-cell malignancies.

Disease	Sample type	Cohort		Initial miRNA selection	Method	Expression	Ref
DLBCL	FFPE	90 DLBCL cases; 31 controls		Previous research	RT-qPCR	↑	[32]
DLBCL	CS	75 DLBCL cases; 10 controls	T	Global screening	Microarray	↑	[46]
	FFPE	47 DLBCL cases; 15 controls	V		RT-qPCR	↑
DLBCL	Blood	20 DLBCL cases; 20 controls	T	Previous research	RT-qPCR	↑	[37]
		75 DLBCL cases; 77 controls	V			↑
DLBCL	FFPE	80 DLBCL cases; 12 controls		Global screening	Microarray	↑	[33]
		80 DLBCL cases; 18 FL cases				NS
DLBCL	FFPE	11 PCNSL cases; 10 nDLBCL cases		Previous research	RT-qPCR	↑	[47]
DLBCL	CS, FFPE	35 DLBCL cases; 12 controls		Global screening	RT-qPCR	↑	[34]
		35 DLBCL cases; 27 FL cases				NS
DLBCL	CS, FFPE	18 DLBCL cases; 5 controls		Previous research	RNA-ISH	↑	[48]
					RT-qPCR	↑
DLBCL	CS	29 DLBCL cases; 12 BL cases	T	Global screening	Microarray	↑	[38]
	FFPE	43 DLBCL cases; 28 BL cases	V		RT-qPCR	↑
DLBCL	Blood	60 DLBCL cases; 43 controls		Previous research	RT-qPCR	↑	[35]
DLBCL	FFPE	19 DLBCL cases; 31 exN DLBCL cases		Previous research	RT-qPCR	NS	[49]
DLBCL	CS	22 DLBCL cases; 7 controls		Previous research	RT-qPCR	↑	[50]
DLBCL	CS	79 DLBCL cases; 36 BL cases		Global screening	Microarray	↑	[39]
DLBCL	CS	23 DLBCL cases; 2 controls		Previous research	RT-qPCR	↑	[51]
DLBCL	FNAB	45 DLBCL cases; 33 BL cases		Previous research	RT-qPCR	↑	[40]
		45 DLBCL cases; 19 DLBCL/BL cases				↑
DLBCL	FFPE	200 DLBCL cases; 11 controls		Previous research	RT-qPCR	↑	[52]
DLBCL	CS	10 DLBCL EBV− cases; 11 DLBCL EBV+ cases		Global screening	Sequencing	↑	[53]
					RT-qPCR	NS
DLBCL	FFPE	58 DLBCL cases; 7 controls		Global screening	RT-qPCR	↑	[36]
		58 DLBCL cases; 46 FL cases				NS
DLBCL	Ocular fluid	17 retinal DLBCL cases; 12 uveitis cases		Global screening	RT-qPCR	↓	[54]
BL	CS	6 BL; DLBCL (cell line)		Previous research	RT-qPCR	↓	[55]
BL	FFPE; CS	3 BL cases; 2 controls		Previous research	Northern blot	↓	[56]
BL	CS	11 BL cases; 11 controls		Previous research	RT-qPCR	↓	[57]
BL	CS	12 BL cases; 135 other L		Global screening	Microarray	↓	[38]
HL	FFPE	42 HL cases; 8 controls		Global screening	Microarray	NS	[58]
					RT-qPCR	NS
HL	CS	25 HL cases; 7 controls		Previous research	RT-qPCR	↑	[50]
HL	CS, FFPE	5 HL cases; 5 controls		Previous research	RT-qPCR	NS	[48]
MALT	CS	22 MALT cases; 46 controls		Previous research	RT-qPCR	↑	[59]
MALT	CS	4 MALT cases; 4 controls	T	Global screening	Microarray	↑	[60]
		14 MALT cases; 14 controls	V		RT-qPCR	↑
MALT	CS	3 MALT cases; 3 controls	T	Global screening	Microarray	↑	[61]
		20 MALT cases; 20 controls	V		RT-qPCR	↑
FL	BM	5 FL cases; 3 controls		Previous research	RT-qPCR	NS	[62]
SMZL	FFPE	15 SMZL cases; 11 controls		Global screening	RT-qPCR	↑	[63]
SMZL	CS	31 SMZL cases; 15 controls	T	Global screening	Microarray	↑	[64]
	FFPE	77 SMZL cases; 6 controls	V		RT-qPCR	↑
SMZL	CS; FFPE	15 SMZL cases; 9 controls		Global screening	Microarray	↑	[65]
					RT-qPCR	↑
CLL	CS	70 CLL cases; 18 controls		Previous research	RT-qPCR	↑	[66]
CLL	Blood	6 CLL cases; 3 controls		Global screening	Microarray	↑	[67]
CLL	Blood	7 CLL cases; 4 controls		Previous research	Northern blot	↑	[68]
CLL	Blood	69 CLL cases; 15 controls		Global screening	Nanostring	↑	[69]
					RT-qPCR	↑
CLL	Blood	113 CLL cases; 7 controls		Previous research	RT-qPCR	↑	[70]
CLL	Blood	50 CLL cases; 14 controls		Global screening	Microarray	↑	[71]
					RT-qPCR	↑
CLL	Blood	38 CLL cases; 9 controls		Global screening	Microarray	↑	[72]
CLL	Blood	56 CLL cases; 7 controls		Previous research	RT-qPCR	↑	[73]
CLL	Blood	70 CLL cases; 8 controls	T	Previous research	RT-qPCR	↑	[74]
		23 CLL cases; 12 controls	V		RT-qPCR	↑

Disease: DLBCL, diffuse large B-cell lymphoma; BL, Burkitt’s lymphoma; HL, Hodgkin lymphoma; MALT, mucosa-associated lymphoid tissue; FL, follicular lymphoma; SMZL, splenic marginal zone lymphoma; CLL, chronic lymphocytic leukemia. Sample type: FFPE, formalin-fixed paraffin-embedded tissue samples; CS, clinical samples; FNABs, fine needle aspirations. Cohort: controls, nonmalignant tissues; PCNSL, primary CNS lymphoma; nDLBCL, nodal DLBCL; exN DLBCL, extranodal DLBCL; EBV, Epstein-Barr virus; L, lymphoma; control, adjacent normal tissue, T; training set; V, validation set. Method: RT-qPCR, reverse transcription quantitative PCR; RNA-ISH, RNA in situ hybridization. Expression: ↑, increased; ↓, decreased; NS, not significant. Ref: reference.